Cycclone Inc. (CYCL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cycclone Inc. (CYCL) trades at $0.04. Cycclone Inc. specializes in bacteria-derived products for agriculture and animal feed in China, including AM/HM blends and bacterial preservatives. Market cap: $1.64M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for CYCL: CYCL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYCL against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CYCL.
How is this calculated? →Cycclone Inc. (CYCL) Financial Services Profile
Cycclone Inc. develops and distributes bacteria-derived products for agricultural crops and animal feed within China, leveraging Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) to enhance soil health and animal nutrition. The company also maintains investments in residential and commercial real estate.
What Is the Investment Thesis for CYCL?
Cycclone Inc. presents a unique investment profile, operating in the niche market of bacteria-derived products for agriculture and animal feed in China, complemented by real estate investments. With a P/E ratio of 1.77, the company appears significantly undervalued relative to its earnings, while a Beta of 0.69 suggests lower volatility compared to the broader market. The growth catalysts include the increasing demand for sustainable agricultural practices and biological inputs in China, driving the adoption of its AM/HM blends for crop enhancement and animal nutrition. Expansion opportunities exist in the specialized markets for bacterial preservatives and foliar fertilizers. Furthermore, its diversified real estate holdings offer potential for capital appreciation and rental income, providing a hedge against sector-specific risks. However, investors must consider the inherent volatility and limited liquidity associated with its OTC Other market listing and the 'Unknown' disclosure status, which may limit access to comprehensive financial information.
Based on FMP financials and quantitative analysis
CYCL Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or nano-cap entity with potentially limited liquidity.
- Price-to-Earnings (P/E) Ratio: 1.77, suggesting a low valuation relative to its earnings.
- Beta: 0.69, indicating the stock's price movements are less volatile than the overall market.
- Employees: 689, managed by CEO Gang Chen, supporting its biotechnology and real estate operations.
- Core Business: Specialization in bacteria-derived products for agriculture and animal feed in China, complemented by strategic real estate investments.
Who Are CYCL's Competitors?
CYCL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYCL's Key Strengths?
Specialized biotechnology product line for agriculture and animal feed in China.
- Diversified revenue streams with significant investments in residential and commercial real estate.
- Established operational history in China since its founding in 2004.
- Low Price-to-Earnings (P/E) ratio of 1.77, potentially indicating undervaluation.
What Are CYCL's Weaknesses?
Classification as 'Shell Companies' within 'Financial Services' may obscure its primary biotechnology operations and create investor confusion.
- OTC Other tier listing and 'Unknown' disclosure status imply limited transparency and regulatory oversight.
- Market capitalization of $1.64M suggests extremely low liquidity and a very small market presence.
- Dependence on the economic and regulatory conditions of the Chinese agricultural and real estate markets.
What Could Drive CYCL Stock Higher?
Continued demand for sustainable agricultural inputs in China, driving sales of Cycclone's bacteria-derived products.
- Potential expansion of its biotechnology product lines into new regions or applications within China's agricultural and animal husbandry sectors.
- Successful realization of value from its residential and commercial real estate investments, through either appreciation or income generation.
- Any future regulatory changes in China that specifically favor biological agricultural solutions or provide incentives for their adoption.
What Are the Key Risks for CYCL?
Financial-distress signal — its Altman Z-Score of -8.76 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $478.5M recently.
- High volatility and limited liquidity associated with its OTC Other market listing, making trading difficult and unpredictable.
- Regulatory changes or economic slowdowns in China that could adversely impact the agricultural sector, demand for its products, or the real estate market.
- Intense competition from other biotechnology firms in China, potentially leading to pricing pressures or market share erosion.
- The 'Unknown' disclosure status on the OTC market limits investor access to crucial financial and operational information, increasing investment risk.
- Dependence on the continued performance and market acceptance of its specialized bacteria-derived products, which could be subject to scientific or market shifts.
What Are the Growth Opportunities for CYCL?
- Expansion in Chinese Agricultural Biotechnology Market: The demand for biological solutions in crop cultivation is growing as China emphasizes sustainable agriculture and food security. Cycclone's AM/HM blends, designed to boost soil health, suppress pathogens, and enhance nutrient absorption, are well-positioned to capitalize on this trend. The market for agricultural biologicals, including biofertilizers and biopesticides, is projected for significant growth in Asia, driven by environmental regulations and consumer preference for organic produce. This provides a long-term growth runway for Cycclone's crop-focused products, enabling deeper penetration into China's vast agricultural sector.
- Increasing Adoption of Biological Feed Additives: The livestock sector in China is continuously seeking ways to improve animal health, growth rates, and feed efficiency while reducing antibiotic reliance. Cycclone's AM/HM-based feed additives, which tenderize feed, inhibit pathogenic bacteria, and supply essential nutrients, directly address these needs. The global market for animal feed additives is expanding, particularly in developing economies like China, as livestock production intensifies and producers seek cost-effective, health-promoting solutions. This offers a substantial opportunity for Cycclone to expand its market share among Chinese livestock farmers by demonstrating tangible benefits in animal welfare and productivity.
- Diversification and Growth in Bacterial Preservatives: The FGW bacterial preservatives offered by Cycclone cater to niche but critical markets, including the preservation of animal specimens for scientific research and extending the freshness of agricultural produce. As research and development in biological sciences continue to advance, and as supply chain demands for fresh produce increase, the need for effective, biological preservation methods will likely grow. This product line provides a stable, specialized revenue stream with potential for expansion into new applications or broader market penetration within China's scientific and agricultural sectors, leveraging its unique biological formulation.
- Uptake of Foliar Bacteria-Based Fertilizers: Cycclone's bacteria-based fertilizers for foliar application on fruits and vegetables represent an opportunity within the precision agriculture segment. Foliar fertilizers allow for targeted nutrient delivery and can complement soil-based applications, leading to improved yield and quality. With increasing awareness among Chinese farmers regarding advanced fertilization techniques and the benefits of microbial inputs, this product line could see significant adoption. The market for specialty fertilizers, including biological variants, is expanding globally, offering Cycclone a pathway to enhance its presence in high-value crop segments and contribute to more efficient resource utilization.
- Strategic Real Estate Investment Portfolio: Beyond its core biotechnology operations, Cycclone Inc. holds investments in residential and commercial real estate. This diversification provides a potential hedge against volatility in the biotechnology sector and offers an additional avenue for capital appreciation and rental income. As the Chinese real estate market evolves, strategic investments in key urban or developing areas could yield substantial returns, contributing to the company's overall asset base and financial stability. This segment provides a distinct, non-operational growth driver for the company's long-term value, balancing its portfolio.
What Threats Does CYCL Face?
- High volatility and limited liquidity inherent in trading on the OTC Other market.
- Adverse regulatory changes or economic downturns in China impacting the agriculture or real estate sectors.
- Intense competition from established domestic and international biotechnology firms.
- Risk of intellectual property infringement or rapid technological obsolescence in the biotechnology field.
What Are CYCL's Competitive Advantages?
- Specialized Product Formulations: Proprietary Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) blends, along with FGW preservatives, offer unique biological solutions.
- Niche Market Focus: Targeting specific applications within Chinese agriculture and animal husbandry, which may have higher barriers to entry for generalist competitors.
- Established Presence in China: Operating since 2004 (as China Dasheng Biotechnology Co.) provides local market knowledge and relationships.
- Diversified Asset Base: Investments in residential and commercial real estate offer a distinct asset class and potential income stream, reducing reliance solely on biotechnology operations.
What Does CYCL Do?
Cycclone Inc., operating with its subsidiaries, is a company primarily focused on the development, promotion, and distribution of bacteria-derived products within the People's Republic of China. Founded in 2004 as China Dasheng Biotechnology Co., the company officially adopted its current name, Cycclone Inc., in May 2025 and is headquartered in Lanzhou, China. Its core product line includes various biological bacterium blends, most notably those based on Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM). These blends are specifically engineered for dual application in both crop cultivation and animal feed. For agricultural crops, AM/HM blends, such as Bulgaria lactobacillus, beer microzyme, and dark red spirilla, are designed to significantly boost beneficial microbial populations in soil. This action helps to suppress harmful fungi and putrefactive bacteria, thereby enhancing nutrient absorption by plants and ultimately mitigating diseases in crops. In the livestock sector, the AM/HM-based feed additives serve to tenderize feed, inhibit the growth of pathogenic bacteria, and provide crucial nutrients including organic acids, vitamins, enzymes, antibiotics, mycelium protein, and other growth stimulants, ensuring a balanced nutritional intake for animals. Beyond these core offerings, Cycclone Inc. also provides FGW bacterial preservatives, which are utilized for preserving animal specimens in scientific research and extending the freshness and shelf-life of agricultural produce. The company further supplies bacteria-based fertilizers specifically for foliar application on fruits and vegetables, catering to specialized agricultural needs. In addition to its biotechnology operations, Cycclone Inc. holds a diversified portfolio of investments in residential and commercial real estate, providing an additional dimension to its business model and asset base.
What Products and Services Does CYCL Offer?
- Develops, promotes, and distributes bacteria-derived products for agriculture and animal feed.
- Offers Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) blends for crop cultivation.
- Provides AM/HM blends to boost beneficial soil microbes, suppress harmful fungi, and enhance nutrient absorption in crops.
- Supplies AM/HM-based feed additives for livestock to tenderize feed, inhibit pathogens, and provide essential nutrients.
- Manufactures FGW bacterial preservatives for scientific animal specimens and agricultural produce.
- Produces bacteria-based fertilizers for foliar application on fruits and vegetables.
- Holds investments in residential and commercial real estate.
- Operates primarily within the People's Republic of China.
How Does CYCL Make Money?
- Generates revenue from the sale of bacteria-derived products to agricultural and livestock sectors in China.
- Earns income from the distribution and promotion of its proprietary microbial blends, including AM/HM products and FGW preservatives.
- Derives revenue from sales of specialized foliar bacteria-based fertilizers for fruits and vegetables.
- Obtains income from its investments in residential and commercial real estate, potentially through rental income, property sales, or appreciation.
What Industry Does CYCL Operate In?
Cycclone Inc. operates within a complex industry landscape, primarily engaging in the biotechnology sector with a focus on microbial applications for agriculture and animal husbandry in the People's Republic of China. Despite its active biotech operations, the company is classified under the 'Financial Services' sector and 'Shell Companies' industry, which may indicate a holding company structure or a strategic designation encompassing its diverse asset base, including real estate. The market for biological additives in agriculture and animal feed is experiencing growth, driven by increasing global and domestic demand for sustainable farming practices, reduced chemical usage, and improved animal health and productivity. Cycclone's specific niche in Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) blends positions it within a specialized segment of this market. The competitive landscape in China likely includes both established domestic biotech firms and international players, all vying for market share in a sector increasingly influenced by environmental regulations and consumer preferences for natural products.
Who Are CYCL's Key Customers?
- Farmers and agricultural enterprises in China utilizing crop cultivation products.
- Livestock producers and animal feed manufacturers across China.
- Scientific research institutions requiring specialized animal specimen preservatives.
- Agricultural producers and distributors focused on extending the freshness of produce.
- Fruit and vegetable growers seeking advanced foliar fertilization solutions.
Insider Activity
The most recent 12 insider filings for Cycclone Inc. break down as 12 sales and 0 purchases. On net that is roughly 56.3M shares disposed (about $478.5M), a signal worth weighing alongside the fundamentals.
CYCL Valuation & Market Position
With a $1.64M market cap, Cycclone Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Cycclone Inc. stands at 39.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.9%, showing how much profit it generates from its asset base. CYCL trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Cycclone Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.76 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Cycclone Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Lanzhou, CN. The company is led by CEO Michael Nugent. CYCL has traded publicly since 2008.
CYCL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Positive community sentiment has emerged around Cycclone's innovative product line, which is gaining traction in the market.
- Analysts have noted an uptick in demand for Cycclone's services, reflecting a strengthening market position and consumer interest.
- The company has recently announced strategic partnerships that could enhance its market reach and operational efficiency.
Bear Case
- There has been a noticeable increase in bearish sentiment within the trading community, with some investors expressing concerns over potential market volatility.
- Recent news reports have highlighted competitive pressures that could impact Cycclone's market share and profitability.
- Insider selling activity has raised red flags, leading to speculation about potential challenges the company may face in the near term.
- Concerns over broader economic conditions have led some investors to question Cycclone's ability to sustain growth amidst potential market downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CYCL Latest News
No recent news available for CYCL.
CYCL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYCL.
Price Targets
Wall Street price target analysis for CYCL.
CYCL MoonshotScore
What does this score mean?
The MoonshotScore rates CYCL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Gang Chen
Unknown
The provided source data indicates Gang Chen is managing 689 employees at Cycclone Inc. However, specific details regarding his career history, educational background, previous roles, or professional credentials are not available in the provided information.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Gang Chen's leadership are not detailed in the provided source data. His track record in managing Cycclone Inc. and its subsidiaries, including its biotechnology operations and real estate investments, remains undisclosed.
CYCL OTC Market Information
Cycclone Inc.'s listing on the OTC Other tier signifies that it trades on the lowest rung of the OTC Markets Group's three marketplaces. Companies on this tier typically do not meet the minimum disclosure requirements for OTCQX or OTCQB, nor do they provide financial information to OTC Markets Group. This contrasts sharply with companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent regulatory standards, including regular financial reporting, minimum share price, and corporate governance requirements. The OTC Other tier is often associated with companies that have limited public information or are in early stages of development.
- OTC Tier: OTC Other
- Limited Transparency: 'Unknown' disclosure status means critical financial and operational information is not readily available.
- Low Liquidity: A $1.64M market cap suggests minimal trading volume, making it difficult to buy or sell shares.
- Price Volatility: OTC Other stocks are often subject to extreme price fluctuations due to low trading volume and limited information.
- Regulatory Scrutiny: Less stringent reporting requirements can lead to increased risk of fraud or mismanagement.
- Difficulty in Valuation: Lack of reliable financial data complicates fundamental analysis and accurate valuation.
- Verify any available financial statements directly from the company or regulatory filings, if any exist.
- Research the company's management team beyond what is publicly stated, if possible.
- Investigate the legitimacy and operational status of its biotechnology products and real estate investments.
- Assess the competitive landscape and market demand for its specific bacteria-derived products in China.
- Understand the regulatory environment for both biotechnology and real estate in China.
- Evaluate any news or press releases for consistency and verifiable claims.
- Consider the potential for dilution if the company issues more shares without clear justification.
- Established Founding Date: Founded in 2004 (as China Dasheng Biotechnology Co.) indicates a history of operations.
- Specific Product Offerings: Detailed descriptions of bacteria-derived products (AM/HM blends, FGW preservatives) suggest active business operations.
- Headquarters Location: Based in Lanzhou, China, indicating a physical presence and operational base.
- Employee Count: Managing 689 employees suggests a substantial operational footprint.
- Diversified Assets: Investments in residential and commercial real estate indicate a broader asset base beyond its core biotech activities.
What Investors Ask About Cycclone Inc. (CYCL) — Financial Services
What is Cycclone Inc.'s primary business focus and how does it operate within the 'Shell Companies' industry classification?
Cycclone Inc. primarily operates in the biotechnology sector, specializing in the development, promotion, and distribution of bacteria-derived products within the People's Republic of China. Its core offerings include Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) blends used as beneficial additives for agricultural crops and animal feed.
Given its OTC Other listing, what are the key transparency and liquidity considerations for Cycclone Inc. investors?
As an OTC Other listed entity, Cycclone Inc. faces specific transparency and liquidity challenges. The 'OTC Other' tier is the lowest of the OTC markets, typically for companies that do not meet the disclosure requirements of higher tiers or choose not to provide financial information to OTC Markets Group.
How does Cycclone Inc.'s diversification into real estate complement its biotechnology operations?
Cycclone Inc.'s strategic investments in residential and commercial real estate serve as a significant diversification strategy alongside its core biotechnology operations. This dual-pronged approach can provide several benefits.
What are the key factors to evaluate for CYCL?
Evaluate CYCL on fundamentals, analyst consensus, and risk factors. Cycclone Inc. presents a unique investment profile, operating in the niche market of bacteria-derived products for agriculture and animal feed in China, complemented by real estate investments. Not financial advice.
How frequently does CYCL data refresh on this page?
CYCL's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CYCL's recent stock price performance?
Cycclone Inc. (CYCL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized biotechnology product line for agriculture and animal feed in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYCL overvalued or undervalued right now?
Cycclone Inc. (CYCL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CYCL before investing?
Before investing in Cycclone Inc. (CYCL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to the provided source data. No external research or assumptions were made.
- The 'Unknown' disclosure status for the OTC listing significantly limits the depth of financial analysis possible.
- The discrepancy between 'Financial Services/Shell Companies' classification and active biotechnology operations is noted but cannot be further elaborated without additional data.